Effect of anti-epileptic drugs on serum immunoglobulin levels in children

Acta Neurologica Belgica

Volumn 110, Issue 1, 2010, Pages 65-70

  Ashrafi, Mahmoudreza ^a   Hosseini, Seyed Ahmad ^a   Abolmaali, Sarah ^b   Biglari, Mohammad ^b   Azizi, Reza ^a   Farghadan, Maryam ^c   Samadian, Azam ^c   Saghafi, Shiva ^c   Mombeini, Hoda ^b   Saladjegheh, Narges ^d   Rezaei, Nima ^a,b   Aghamohammadi, Asghar ^a,b  

^a Children's Medical Center   (United States)

^b Growth and Development Research Center   (United States)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Clinical Laboratory Maryam Hospital   (Iran)

Author keywords

Antiepileptic drugs; Epilepsy; IgA; Immuno globulin

Indexed keywords

CARBAMAZEPINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHENOBARBITAL; VALPROIC ACID; ANTICONVULSIVE AGENT; IMMUNOGLOBULIN;

ABSENCE; ADOLESCENT; ARTICLE; ATONIC SEIZURE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOCAL EPILEPSY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIXED SEIZURE; MONOTHERAPY; PRESCHOOL CHILD; SCHOOL CHILD; TONIC CLONIC SEIZURE; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; EPILEPSY; TIME;

ADOLESCENT; ANTICONVULSANTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; IMMUNOGLOBULINS; MALE; TIME FACTORS;

EID: 77953716935     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Aarli JA. Changes in serum immunoglobulin levels during phenytoin treatment of epilepsy. Acta Neurol Scand. 1976;54(5):423-30.
2. Aarli JA. Epilepsy and the immune system. Arch Neurol. 2000;57(12):1689-92.
3. Aarli JA. Immunological aspects of epilepsy. Brain Dev. 1993;15(1):41-9.
4. Aarli JA, Gilhus NE. Antiepileptic drugs and resistance to infections. In: "Antiepileptic therapy: chronic toxicity of antiepileptic drugs". Oxley J, Janz D, Meinardi H, eds. New York, Raven Press, 1983, 261-7.
5. Aghamohammadi A, Lougaris V, Plebani A, Miyawaki T, Durandy A, Hammarström L. Predominantly antibody deficiencies. In: "Primary immunodeficiency diseases: definition, diagnosis and management". Rezaei N, Aghamohammadi A, Notarangelo LD, eds. Berlin Heidelberg, Springer-Verlag, 2008, 97-130.
6. Aghamohammadi A, Cheraghi T, Gharagozlou M, Movahedi M, Rezaei N. et al. IgA deficiency: correlation between clinical and immunological phenotypes. J Clin Immunol. 2009;29(1):130-6.
7. Aktekin B, Dogan EA, Oguz Y, Senol Y. Withdrawal of antiepileptic drugs in adult patients free of seizures for 4 years: a prospective study. Epilepsy Behav. 2006;8(3):616-9.
8. Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia. 1979;20(6):729-737.
9. Bardana EJ Jr, Gabourel JD, Davies GH, Craig S. Effects of phenytoin on man's immunity. Evaluation of changes in serum immunoglobulins, complement, and antinuclear antibody. Am J Med. 1983;74(2):289-96.
10. Basaran N, Hincal F, Kansu E, Ciger A. Humoral and cellular immune parameters in untreated and phenytoin-or carbamazepine-treated epileptic patients. Int J Immunopharmacol. 1994;16(12):1071-7.
11. Berg AT. The epidemiology of seizures and epilepsy in children. In: "Childhood Seizures". Shinnar S, Amir N, Branski D, eds. Basel, Switzerland, Karger, 1995, 1-10.
12. Berg AT, Shinnar S. The contributions of epidemiology to the understanding of childhood seizures and epilepsy. J Child Neurol. 1994;9(Suppl.): S19-S26.
13. Billiau AD, Wouters CH, Lagae LG. Epilepsy and the immune system: is there a link? Eur J Paediatr Neurol. 2005;9:29-42.
14. Callenbach PM, Jol-Van der Zijde CM, Geerts AT, Arts WF, van Donselaar CA. et al. Immunoglobulins in children with epilepsy: the Dutch Study of Epilepsy in Childhood. Clin Exp Immunol. 2003;132(1):144-51.
15. Callenbach PM, Westendorp RG, Geerts AT, Arts WF, Peeters EA. et al. Mortality risk in children with epilepsy: The Dutch study of epilepsy in childhood. Pediatrics. 2001;107(6):1259-1263.
16. Camfield C, Camfield P, Gordon K, Smith B, Dooley J. Outcome of childhood epilepsy: A populationbased study with a simple predictive scoring system for those treated with medication. J Pediatr. 1993;122(6):861-868.
17. Camfield C, Camfield P, Gordon K, Wirrell E, Dooley JM. Incidence of epilepsy in childhood and adolescence: A population-based study in Nova Scotia from 1977 to 1985. Epilepsia. 1996;37(1):19-23.
18. Camfield P, Camfield C. Long-term prognosis for symptomatic (secondarily) generalized epilepsies: a population-based study. Epilepsia. 2007;48(6):1128-32.
19. Casetta I, Granieri E, Monetti V C, Tola M R, Paolino E. et al. Prognosis of childhood epilepsy: A community-based study in Copparo, Italy. Neuroepidemiology. 1997;16(1):22-28.
20. Castro AP, Redmershi MG, Pastorino AC, de Paz JA, Fomin AB. et al. Secondary hypogammaglobulinemia after use of carbamazepine: case report and review. Rev Hosp Clin Fac Med Sao Paulo. 2001;56(6):189-192.
21. Connolly AM, Chez MG, Pestronk A, Arnold ST, Mehta S. et al. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr. 1999;134:607-13.
22. Cuilliere ML, Montagne P, Bessou T, el Omari R, Riochet D. et al. Microparticle-enhanced nephelometric immunoassay (Nephelia) for immuno - globulins G, A and M. Clin Chem. 1991;37(1):20-5.
23. D'Amelio M, Shinnar S, Hauser WA. Epilepsy in children with mental retardation and cerebral palsy. In: "Epilepsy and Developmental Disability". Devinsky O, Westbrook LE, eds. Boston, Butterworth Heinemann, 2002, 3-16.
24. De Ponti F, Lecchini S, Cosentino M, Castelletti CM, Malesci A. et al. Immunological adverse effects of anticonvulsants. What is their clinical relevance? Drug Saf. 1993;8(3):235-50.
25. Derby LE, Tennis P, Jick H. Sudden unexplained death among subjects with refractory epilepsy. Epilepsia. 1996;37(10):931-935.
26. Garzón P, González-Cornejo S, Román-Maldonado S, Navarro-Ruiz A. Valproic acid and phenytoin effects on serum proteins and immunoglobulins of epileptic patients. Gen Pharmacol. 1985;16(4):411-3.
27. Gilhus NE, Aarli JA. Respiratory disease and nasal immuno globulin concentrations in phenytointreated epileptic patients. Acta Neurol Scand. 1977;56:353-6.
28. Gilhus NE, Aarli JA. The reversibility of phenytoininduced IgA deficiency. J Neurol. 1981;226:53-61.
29. Gilhus NE, Strandjord RE, Aarli JA. The effect of carbamazepine on serum immunoglobulin concentrations. Acta Neurol Scand. 1982;66(2):172-9.
30. Glauser TA. Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients. J Child Neurol. 2004;19 Suppl 1: S25-38.
31. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D. et al. ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094-120.
32. Go T. Carbamazepine-induced IgG1 and IgG2 deficiency associated with B cell maturation defect. Seizure. 2004;13(3):187-90.
33. Hammarström L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin Exp Immunol. 2000;120(2):225-231.
34. Hanson LA, Bjorkander J, Carlsson B, Roberton D, Soderstrom T. The heterogeneity of IgA deficiency. J Clin Immunol. 1988;8(3):159-62.
35. Haraldsson A, van Engelen BG, Renier WO, Bakkeren JA, Weemaes CM. Light chain ratios and concentrations of serum immunoglobulins in children with epilepsy. Epilepsy Res. 1992;13:255-60.
36. Hemingway C, Leary M, Riordan G, Schlegal B, Walker K. The effect of carbamazepine and sodium valproate on the blood and serum values of children from a 3rd world environment. J Child Neurol. 1999;14(11):751-3.
37. Kälviäinen R, Keränen T, Riekkinen PJ Sr. Place of newer antiepileptic drugs in the treatment of epilepsy. Drugs. 1993;46(6):1009-24.
38. Leestma JE, Walczak T, Hughes JR, Kalelkar MB, Teas SS. A prospective study on sudden unexpected death in epilepsy. Ann Neurol. 1989;26(2):195-203.
39. Lenti C, Masserini C, Peruzzi C, Guareschi-Cazzullo A. Effects of carbamazepine and valproate on immunological assessment in young epileptic patients. Ital J Neurol Science. 1991;12(1):87-91.
40. Pacifici R, Paris L, Di Carlo S, Pichini S, Zuccaro P. Immunologic aspects of carbamazepine treatment in epileptic patients. Epilepsia. 1991;32(1):122-7.
41. Ranua J, Luoma K, Auvinen A, Peltola J, Haapala AM. et al. Serum Ig A, Ig G, and Ig M concentrations in patients with epilepsy and matched controls: a cohortbased cross-sectional study. Epilepsy Behav. 2005;6(2):191-5.
42. Rogers SW, Andrews PI, Gahring LC, Whisenand T, Cauley K. et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science. 1994;265:648-51.
43. Ruff ME, Pincus LG, Sampson HA. Phenytoin-induced IgA depression. Am J Dis Child. 1987;141(8):858-61.
44. Sanker R. Initial treatment of epilepsy with antiepileptic drugs. Neurology. 2004;63(10 suppl 4): S30-S39.
45. Sillanpaa M, Jalava M, Kaleva O, Shinnar S. Long-term prognosis of seizures with onset in childhood. N Engl J Med. 1998;338(24):1715-1722.
46. Sillanpää M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain. 2006;129(Pt 3):617-24.
47. Sillanpää M, Schmidt D. Prognosis of seizure recurrence after stopping antiepileptic drugs in seizure-free patients: A long-term population-based study of childhood-onset epilepsy. Epilepsy Behav. 2006;8(4):713-9.
48. Sorrell TC, Forbes IJ. Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro. Clin Exp Immunol. 1975;20(2):273-85.
49. Stiehm ER, Fudenberg HH. Serum levels of immune globulins in health and disease: a survey. Pediatrics. 1966;37(5):715-27.
50. Van Engelen BG, Weemaes CM, Renier WO, Bakkeren JA, Borm GF. et al. A dysbalanced immune system in cryptogenic Lennox-Gastaut syndrome. Scand J Immunol. 1995;41:209-13.
51. Voutsinas D, Foudoulaki L, Sofroniadou K, Galanakis N. Visceral leishmaniasis in a patient with acquired hypogammaglobulinemia. Eur J Int Med. 2001;12:127-129.
52. Wilson SB, Scheuer ML, Emerson RG, Gabor AJ. Seizure detection: evaluation of the Reveal algorithm. Clin Neurophysiol. 2004;115(10):2280-2291.
53. Winckler MI, Rotta NT. Clinical and electroencephalographic follow-up after a first unprovoked seizure. Pediatric Neurol. 2004;30(3):201-206.